Abstract

Multiple myeloma (MM) is a blood cancer that affects 30,000 people yearly in the U.S. It stems from monoclonal plasma cells and can cause symptoms such as bone loss and fatigue. Recent studies have shown that the bone marrow microenvironment may mediate tumor proliferation, drug resistance, and migration of the multiple myeloma cells. Synthetic oleanane triterpenoids have been readily used in research due to their anti‐proliferative and anti‐inflammatory effects. The objective of this study is to examine the anti‐cancer effect of 2‐cyano‐3, 12 dioxoolean‐1,9‐dien‐28‐oic acid (CDDO) derivatives on multiple myeloma cells. Three CDDO derivatives (CDDO‐Methyl Ester (Me), CDDO‐Trifluoethyl Amide (TFEA), and CDDO‐Imidazolide (Im)) with a dose range from 0.1 to 0.5 μM were tested on the growth of MM RPMI 8226 cells within 72 hours. Our current results show that all CDDO derivatives decrease the cell viability and proliferation of the MM 8226 cells in a dose and time‐dependent manner. Based on the potency, CDDO‐Im was selected to study whether its inhibitory effect on MM cell growth is due to the induction of apoptosis. Western blotting was used to check the protein expression of apoptosis‐related factors such as caspase 3, caspase 8, caspase 9 and poly‐(ADP‐ribose) polymerase (PARP). The result indicates that CDDO‐Im may induce the intrinsic apoptotic pathway. To evaluate the effect of CDDO‐Im on MM 8226 cells in the presence of the microenvironment, a Transwell (TW) model using MM cells co‐culturing with bone marrow stromal cells will be applied to mimic the bone marrow microenvironment in vivo. When treating the HS‐5 stromal cells with CDDO‐Im, no significant decrease in proliferation was seen after 24 hours. We expect that after co‐culturing the MM 8226 cells with HS‐5 stromal cells using the TW model, the growth of MM cells will still be prohibited by CDDO‐Im to some extent if not the same as MM cells being treated alone. In conclusion, our data suggest that CDDO derivatives inhibit the growth of MM cells through induction of apoptosis.Support or Funding InformationPCOM Division of Research FundingThis abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.